Author reply: To PMID 24359625

Affiliations

¹ Department of Ophthalmology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama.
² Tampa Bay Uveitis Center, Tampa, Florida.
³ Departments of Ophthalmology and Medicine, the Mount Sinai Medical School, New York, New York; Department of Epidemiology, the Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
⁴ Departments of Ophthalmology and Medicine, Division of Rheumatology, Oregon Health & Science University, Portland, Oregon; Department of Ophthalmology, Legacy Devers Eye Institute, Portland, Oregon.
⁵ Department of Ophthalmology, Moran Eye Institute, University of Utah School of Medicine, Salt Lake City, Utah.
⁶ Departments of Ophthalmology, Pathology, and Biological Structure, University of Washington School of Medicine, Seattle, Washington.

Comment

Russell W Read et al. Ophthalmology. 2014 Oct.

. 2014 Oct;121(10):e58-9.

doi: 10.1016/j.ophtha.2014.05.034. Epub 2014 Jul 9.

¹ Department of Ophthalmology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama.
² Tampa Bay Uveitis Center, Tampa, Florida.
³ Departments of Ophthalmology and Medicine, the Mount Sinai Medical School, New York, New York; Department of Epidemiology, the Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
⁴ Departments of Ophthalmology and Medicine, Division of Rheumatology, Oregon Health & Science University, Portland, Oregon; Department of Ophthalmology, Legacy Devers Eye Institute, Portland, Oregon.
⁵ Department of Ophthalmology, Moran Eye Institute, University of Utah School of Medicine, Salt Lake City, Utah.
⁶ Departments of Ophthalmology, Pathology, and Biological Structure, University of Washington School of Medicine, Seattle, Washington.

No abstract available

Comment on

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Levy-Clarke G, et al. Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17. Ophthalmology. 2014. PMID: 24359625
Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96).
Onal S, Tugal-Tutkun I. Onal S, et al. Ophthalmology. 2014 Oct;121(10):e57-8. doi: 10.1016/j.ophtha.2014.05.033. Epub 2014 Jul 23. Ophthalmology. 2014. PMID: 25064722 No abstract available.